[Skip to Content]
[Skip to Content Landing]
November 21, 1931

Scharlach: Ätiologie, antitoxische Serumtherapie und Schutzimpfung.

JAMA. 1931;97(21):1560. doi:10.1001/jama.1931.02730210058033

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The purposes of this monograph as stated in the preface are to recommend use of the name Moser-Dick serum instead of Dochez-Dick serum to designate scarlet fever antitoxin, and to orient the physician with regard to recent developments in scarlet fever. The reasons advanced in support of the name Moser-Dick serum are that Moser was the first to attempt to produce a serum specific for scarlet fever and that the Dicks discovered scarlet fever antitoxin and developed a successful method for producing it. American readers who are accustomed to use the serum under its scientific descriptive name, Scarlet Fever Antitoxin, will not understand Kraus's insistence on the hyphenated historical name unless they know of his long association with the State Serum Institute in Vienna, where Moser produced his antistreptococcus serum twenty years ago, when Kraus was an assistant in the institute, of which he later became director. The failure of

First Page Preview View Large
First page PDF preview
First page PDF preview